Member Info for MCB55

I trust that the "tweaks" to the LFT will not compromise any approvals!?

greedo,
Distinctly possible we get a good LFT RNS before long (this month?), a relaunch anyway! I doubt we will have news on potential sales/contracts though just yet, more that they , Abingdon and Medusa 19 are back in business! Diagnostics is still a major arm of Avacta and they will be doing everything possible to make it a success and bring in early revenue to support the Therapeutics arm.

Why was the RNS so brief I wonder!? AS could have have explained that a 50% dose escalation meant limited to no side effects! This is massively encouraging news and not obvious to a layman.
Was he in a hurry because he was in the middle of 3 day event or just being naturally conservative at this stage. Almost any other CEO would have been lauding up big style, maybe it is just Yorkshire reticence!? Maybe he has been advised to play it cool after all of the LFT ramping.

There was on 24th Feb 2021, so maybe "shortly"!?

I didn't expect to be below £1 on the Av6000 news that's all, so any dip is disappointing, but as you say not material as just day traders!

No its largely due to no revenue!
End of year financial update to prove adequate finance for next 12+ mths and also LFT relaunch plus sales will stabilise and drive the sp upwards.

Also II's have investment committees to convene and contemplate their navels before any commitment, to the AIM market in particular! Here's hoping though.

Also another rabbit out of the hat due shortly (?) is the LFT relaunch, I wonder what was said about that over the 3 days!?

"it is currently paused to improve efficacy issues that were identified, it’s not been withdrawn or mothballed, information on the test is likely the next big RNS imo and plenty of countries will still be interested in a best in class LFT!"

It will be 4 weeks of a "pause" by end of week, so the new test could be back on the market in a couple of weeks or so! imo.

"Also, lets not forget that given this first dose escallation its likely that the safety margin for delivery of Dox has already been improved to a degree so Avacta already has a better version of Dox on its hands"
Totally agree, this is an important point, we are already better than standard, as side effects are limited for the same dose!

Hopefully some the II”s at these meetings will understand and have a longer time horizon than you average AIM punter! They should be buying in next week!?

Thats ok if the II's buy big, it will move the sp!

Even if AS makes a few inadvertent slips in his talks, that in itself will not substantially move the sp, we all know the trial is going well anyway! What we don't have though is a definitive statement/RNS, only that will move and sustain the sp.

I don't think hard nosed II's will be investing without some a hard factual update
( not possible right now as AS has to inform all shareholders at the same time). However I think that they will be duly impressed and put Avacta on their watch list. Brokers like Hargreaves may just put out a speculative buy note to their clients.
So, overall maybe not an immediate sp transformation, without news, but increasing the audience before a curtain raise!

I think that Avacta need Medical Authority (MHRA?) approval before dosing the second cohort (at an escalated level), which will require a detailed report submitted and reviewed on outcome of first cohort (which is about now/shortly, according to Ophidian). AS to RNS this inflexion point?

Also can we expect an RNS on the first dosing of a US patient, likely in 1Q22?

Quite possibly, that indicates Ph1a not completing until end 2Q22!
So the question is, will there be an interim statement/RNS, as per Ophidian, that advises the start of next cohort dosing (at an escalated level) as part of Ph1a sometime shortly / late 1Q22?

Exhibit 5: AVA6000 Phase I trial design and timeline........It was in the Trinity
note in June 21.

WD,
If Jupiter were on the ball, the risk/reward balance is now definitely against them!
I think it might be possible that they are doing some sort of fancy hedging, balancing longs with shorts......don't really know how that works though!

Ophidian,
I agree all indicators point to a success with AV6000 Ph1a, however the timescale to a potential RNS is my query. The Avacta bar chart Exhibit 5 shows Ph1a not being complete until end 1Q22 and Ph1b starting early 2Q22. So can we reasonably expect an RNS before end 1Q22, as there needs to be a bit of review time between end of first phase and start of next?

You would have thought that Jupiter would have achieved their target by now and be closing!?